JBN Biotech ApS: Financial statements 2023
CVR: 40685693
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
JBN Biotech ApS (CVR 40685693) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -24,987 and a net result of DKK -184,457 compared with DKK 31,880,629 the year before. Equity in the 2023 report amounted to DKK 35,427,442. The solvency ratio was 75.6%.
- Gross Profit
- DKK -24,987
- Profit/Loss
- DKK -184,457
- Equity
- DKK 35,427,442
- Total Assets
- DKK 46,859,471
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -25 t. | -184 t. | 35.4 mio. | 0 |
| 2022 | - | -16 t. | 31.9 mio. | 35.6 mio. | 0 |
| 2021 | - | -16 t. | 4.3 mio. | 3.7 mio. | 0 |
| 2020 | - | -27 t. | -646 t. | -606 t. | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationAbout JBN Biotech ApS
JBN Biotech ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2019. The company is registered under the industry Anden finansiel formidling i.a.n.. The management consists of Jens Bredal Nielsen. The company is owned by Jens Bredal Nielsen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -22,188 and a net result of DKK -222,807 compared with DKK -263,330 the year before. Equity in the 2025 report amounted to DKK 34,941,304.